Should You Buy Ensysce Biosciences Inc (ENSC) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.720
1 Day change
-8.63%
52 Week Range
7.360
Analysis Updated At
2026/01/28
ENSC is not a good buy right now for a beginner long-term investor with $50k–$100k who wants to act immediately. The stock is in a strong downtrend (bearish moving averages) and the latest quarter (2025/Q3) shows sharply deteriorating fundamentals (major revenue decline and widening losses). While it may be short-term oversold and could bounce near support, the risk/reward is not attractive for a long-term, beginner-friendly purchase today.
Technical Analysis
Price/Trend: The broader trend is bearish (SMA_200 > SMA_20 > SMA_5), indicating sustained downward momentum.
Momentum: RSI_6 at ~26.5 signals oversold conditions (often associated with potential short-term bounces), but oversold alone is not a reliable buy signal in a downtrend.
MACD: Histogram is positive (0.0126) but “positively contracting,” suggesting bullish momentum is fading rather than strengthening.
Levels: Current post-market price (~0.782) is below S1 (0.788) and near S2 (0.742). That places the stock at/under support—possible technical bounce zone, but also a sign support is failing. Immediate upside resistance sits around the pivot (0.862) then R1 (0.936).
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
- Patent/IP catalyst: Notice of Allowance from the Brazilian Patent Office for TAAP™ and MPAR® technologies (2026-01-21), which may improve perceived long-term platform value and partnering potential.
- Technically oversold (RSI ~26.5), which can sometimes trigger short-term rebounds.
Neutral/Negative Catalysts
- Strong bearish trend (moving averages stacked bearishly) and the stock is trading below a key support (S1), increasing the odds of continued weakness.
- No supportive institutional/insider trend noted recently (both neutral), and no congress trading signals.
- The business performance in the latest reported quarter shows severe contraction and widening losses, which is typically negative for long-term conviction.
Financial Performance
Latest quarter: 2025/Q3.
- Revenue: $493,104, down ~85.6% YoY (sharp contraction).
- Net income: -$3.73M, down ~663.5% YoY (loss widened substantially).
- EPS: -1.29, down ~229% YoY (meaningfully worse).
- Gross margin: 100% (not improving YoY), but the key issue is collapsing revenue and worsening losses.
Overall: Financial trends are deteriorating, which is unfavorable for a long-term buy today.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so there is no clear Wall Street consensus to lean on. Based on the available data alone, the main 'pro' case is the IP/patent progress, while the main 'con' case is the steep revenue decline, widening losses, and a clearly bearish price trend—tilting the overall view negative for a long-term beginner entry right now.
Wall Street analysts forecast ENSC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENSC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast ENSC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENSC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
